Interested in learning more?
Click here to contact a member of the Day One Clinical team
FIREFLY-2:
Tovorafenib, an investigational, oral, pan-RAF inhibitor versus standard of care chemotherapy being studied in pediatric patients with RAF-altered low-grade glioma requiring front-line systemic therapy
FIRELIGHT-1:
Tovorafenib, an investigational, oral, pan-RAF inhibitor being studied in adolescent and adult patients with recurrent or progressive solid tumors with MAPK pathway alterations
FIREFLY-1:
Tovorafenib, an investigational, oral, pan-RAF inhibitor being studied in pediatric patients with recurrent or progressive low-grade glioma and advanced solid tumors with RAF alterations